Details, Fiction and Clinical effectiveness of ABBV-744 in AML patients
In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Members will acquire treatment till sickness progression or even the members are unable to tolerate the study drugs.Ubiquitin-similar proteins that regulate the stability of critical Tremendous enhancer-mediated proteins ha